Clinical Trial

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 26, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line treatment with Osmertinib, who were randomly assigned to trial group 1 and trial group 2, and were given Furmonertinib 160 mg and 240 mg once/day, orally, respectively, with efficacy evaluated every 6 weeks until disease progression, intolerable toxic side effects, or Subjects voluntarily withdrew informed consent.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-27; most recent amendment 2024-07-25.
Trial Details
NCT Number NCT06394674
Lead Sponsor Changhai Hospital
Collaborators: The General Hospital of Eastern Theater Command, Shanghai Chest Hospital, Fujian Provincial Hospital, Shanghai Changzheng Hospital, The First Affiliated Hospital of Bengbu Medical University, The First People's Hospital of Changzhou, Second Affiliated Hospital of Wannan Medical College
Conditions Non-Small Cell Lung Cancer
Enrollment 84 participants
Start Date 2024-05-01
Primary Completion 2025-06 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2024-07-26